Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-03-07
2009-02-10
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S155100, C424S181100, C424S183100, C435S069600, C530S387300, C530S388100, C530S388800, C530S391700
Reexamination Certificate
active
07488475
ABSTRACT:
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchillin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 2004/0105816 (2004-06-01), Young et al.
patent: 2005/0002940 (2005-01-01), Young et al.
patent: 266032 (1988-05-01), None
patent: 404097 (1990-12-01), None
patent: WO9311161 (1993-06-01), None
patent: WO0034317 (2000-06-01), None
Campbell et al. Biology, 5th ed. p. 856, 1999.
L. Belanger et al, “Enzyme-linked immunoassay for alpha-fetoprotein by competitive and sandwich procedures”, Clinica Chimica Acta., 48:15-18 (1973).
D. Blakey et al, “Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models”, Clinical Cancer Research, 8:1974-1983 (Jun. 2002).
N. Campbell et al, “Methods: Monoclonal antibody technology”, Biology, 5th ed., pp. 856 (1999).
P. Capel et al, “Heterogeneity of human IgG Fc receptors”, Immunomethods, 4:25-34 (1994).
M. Chatterjee et al, “Idiotypic antibody immunotherapy of cancer”, Cancer Immunol. Immunother., 38:75-82 (1994).
C. Chothia et al, “Canonical structures for the hypervariable regions of immunoglobulins”, J. Mol. Biol., 196:901-917 (1987).
T. Clackson et al, “Making antibody fragments using phage display libraries”, Nature, 352:624-628 (Aug. 1991).
R. Clynes et al, “Fc receptors are required in passive and active immunity to melanoma”, Proc. Natl. Acad. Sci. USA, 95:652-656 (Jan. 1998).
M. Co et al, “Humanized antibodies for therapy”, Nature, 351(6):501-502 (Jun. 1991).
S. Eckhardt et al, “Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds”, ASCO Educational Book, 39th Annual Meeting, pp. 209-219 (2003).
B. Froehler et al, “Synthesis of DNA via deoxynucleoside H-phosphonate intermediates”, Nucleic Acids Research, 14(13):5399-5407 (1986).
H. Gazzano-Santoro et al, “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody”, J. Immunol. Methods, 202:163-171 (1997).
S. Guichard et al, “Schedule dependent activity of topotecan in OVCAR 3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation”, Clinical Cancer Research, 7:3222-3228 (Oct. 2001).
N. Guilbard et al, “Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors”, Clinical Cancer Research, 7:2573-2580 (Aug. 2001).
R. Guyer et al, “Immunoglobin binding by mouse intestinal epithelial cell receptors”, J. Immunol., 117(2):587-593 (Aug. 1976).
M. De Haas et al, “Review articles: FCy receptors of phagocytes”, J. Lab Clin. Med., 126:330-341 (1995).
S. Hirschfeld et al, “Oncology drug development: United States Food and Drug Administration Perspective”, Critical Reviews in Oncology/Hematology, 42:137-143 (2002).
P. Holliger et al, “Diabodies: small bivalent and bispecific antibody fragments”, Proc. Natl. Acad. Sci. USA, 90:6444-6448 (Jul. 1993).
R. Jain, “Barriers to drug delivery in solid tumors”, Sci. Am., 271(1):58-65 (Jul. 1994).
E. Kabat et al, “Sequences of proteins of immunological interest”, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).
T. Karpanen et al, “Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth”, Cancer Research, 61:1786-1790 (Mar. 2001).
G. Klement et al, “Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR 2 antibody in multidrug resistant human breast cancer xenografts”, Clinical Cancer Research, 8:221-232 (Jan. 2002).
J. Kim et al, “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor”, Eur. J. Immunol., 24:2429-2434 (1994).
G. Kohler et al, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, 256:495-497 (Aug. 1975).
J. Marks et al, “By-passing immunization human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol., 222:581-597 (1991).
M. Daeron, “Fc receptor biology”, Annu. Rev. Immunol., 15:203-234 (1997).
S. Morrison et al, “Chimeric human antibody molecules: mouse antigen binding domains with human constant region domains”, Proc. Natl. Acad. Sci. USA, 81:6851-6855 (Nov. 1984).
K. Olson et al, “Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody”, Int. J. Cancer, 98:923-929 (2002).
A. Pluckthun, “Antibodies fromEscherichia coli”, Handbook of Experimental Pharmacology, vol. 113, Chapter 11, pp. 269-315, Springer-Verlag, New York (1994).
L. Presta et al, “Engineering therapeutic antibodies for improved function”, Biochemical Society Transactions, 30 (4):487-490 (2002).
J. Ravetch et al, “Fc receptors”, Annu. Rev. Immunol., 9:457-492 (1991).
E. Rubinstein et al, “CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins”, Eur. J. Immunol., 26:2657-2665 (1996).
S. Seaver, “Monoclonal antibodies in industry: more difficult than originally thought”, Genetic Engineering News, 14 (14):10 and 21 (1994).
S. Shak, “Overview of the trastuzumab (Herceptin) anti-HER monoclonal antibody clinical program in HER2 overexpressing metastatic breast cancer”, Seminars in Oncology, 26(4 Suppl 12):71-77 (Aug. 1999).
P. Smith et al, “Anti-interleukin 6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice”, The Prostate, 48:47-53 (2001).
P. Therasse et al, “New guidelines to evaluate the response to treatment in solid tumors”, J. Natl. Cancer Inst., 92 (3):205-216 (Feb. 2000).
V. Von Gruenigen et al, “Efficacy of intraperitoneal adenovirus mediated p53 gene therapy in ovarian cancer”, Int. J. Gynecol. Cancer, 9:365-372 (1999).
W. Waud et al, “Characterization of in vivo mammary and prostate tumor xenograft models for growth and response to clinical anticancer agents”, Contrib. Oncol. Basel. Karger, 54:305-315 (1999).
L. Weiner, “An overview of monoclonal antibody therapy of cancer”, Seminars in Oncology, 26(4 Suppl 12):41-50 (Aug. 1999).
Z. Xiao et al, “Generation of a baculovirus recombinant prostate specific membrane antigen and its use in the development of a novel protein biochip quantitive immunoassay”, Protein Expression and Purification, 19:12-21 (2000).
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
Blanchard David J.
McHale & Slavin P.A.
LandOfFree
Antibody therapy of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody therapy of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody therapy of tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4063008